Please ensure Javascript is enabled for purposes of website accessibility

FibroGen's Anemia Drug Goes to FDA for Review

By Eric Volkman - Feb 12, 2020 at 3:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A decision on Roxadustat should arrive by Dec. 20.

Biotech company FibroGen (FGEN -2.50%) announced Tuesday that its New Drug Application for drug candidate roxadustat, which treats anemia stemming from chronic kidney disease, has been accepted by the Food and Drug Administration.

The regulator has fixed a Prescription Drug User Fee Act (PDUFA) date of Dec. 20 of this year, effectively setting that as the deadline by which it must complete its review.

Red blood cells.

Image source: Getty Images

FibroGen partnered with pharmaceutical giant AstraZeneca (AZN 1.65%) on the drug, an oral treatment that stimulates the production of red blood cells in both dialysis-dependent and non-dialysis-dependent patients. Per the companies' agreement, the FDA's acceptance of the application triggers a $50 million milestone payment from AstraZeneca to FibroGen.

"There is significant unmet medical need for patients with anemia of CKD, who have seen only limited advances in the last three decades," FibroGen said in its press release heralding the news.

CKD, described by the National Kidney Foundation as "the under-recognized public health crisis," affects vast numbers of Americans -- it is estimated that roughly 14% of the U.S. population has the condition. And anemia -- a deficiency of red blood cells -- occurs in nearly one out of four CKD sufferers.

Roxadustat has already been approved in China, and in Japan for patients undergoing dialysis only. FibroGen said its partner Astellas (ALPMY -2.42%) aims to file a marketing authorization application in the first half of this year with the European Union's pharmaceutical review agency.

FibroGen stock closed Wednesday up by about 1.6%. AstraZeneca essential traded sideways, up 0.4%. 


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
$67.02 (1.65%) $1.09
FibroGen, Inc. Stock Quote
FibroGen, Inc.
$10.93 (-2.50%) $0.28
Astellas Pharma Inc. Stock Quote
Astellas Pharma Inc.
$15.75 (-2.42%) $0.39

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.